2. Academic Validation
  3. Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model

Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection Model

  • Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00854-20. doi: 10.1128/AAC.00854-20.
M Ghannoum 1 2,  N Isham 3,  D Angulo 4,  K Borroto-Esoda 4,  S Barat 4,  L Long 3
Affiliations

Affiliations

  • 1 Center for Medical Mycology, Department of Dermatology, Case Western Reserve University, Cleveland, Ohio, USA mahmoud.ghannoum@case.edu.
  • 2 University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
  • 3 Center for Medical Mycology, Department of Dermatology, Case Western Reserve University, Cleveland, Ohio, USA.
  • 4 Scynexis, Inc., Jersey City, New Jersey, USA.
PMID: 32718958 DOI: 10.1128/AAC.00854-20
Abstract

Candida auris has been shown to have a high risk of skin colonization in hospitalized patients, possibly contributing to nosocomial spread. In a guinea pig skin model, Animals were evaluated for clinical appearance, tissue Fungal burden, histology, and pharmacokinetics. Oral dosing with 10 mg/kg ibrexafungerp (IBX) reduced the severity of lesions and significantly reduced the C. auris Fungal burden in infected Animals compared with untreated controls. This indicates promise for use of IBX in controlling skin Infection and colonization of hospitalized patients.

Keywords

Candida auris; cutaneous; ibrexafungerp.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z